Figure 14I illustrated that the low-risk patients appear to be insensitive to immunologic therapy. Importantly, enhanced TIS, NFAG, IFNAP, CD8A, STAT1, and SEPEN1 were clustered in the high-risk group (Figure 14C–H). These results suggested that patients in the high-risk group might be more susceptible to immunologic therapy. Notably, in the GSE91061 and GSE115821 cohorts, BMGs could also predict the effect of immunotherapy on malignant tumors (Figure 14J,K). The gene discussed is STAT1; the disease is cancer.